Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Vargatef 100 mg soft capsules

Active Ingredient:
nintedanib esilate
Company:  
Boehringer Ingelheim Limited See contact details
ATC code: 
L01EX09
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Safety Alert HCP Med Info
{arrow_left}
{arrow_right}
Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection (MHRA release July 2020)

Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors, carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pathway inhibitor, reduce as far as possible any modifiable risk factors such as hypertension.

Further information can be found in the MHRA Drug Safety Update
Boehringer Ingelheim Limited
Company image
Address
Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
WWW
http://www.boehringer-ingelheim.co.uk
Telephone
+44 (0)1344 424 600
Fax
01344 741444
Medical Information Direct Line
+44 (0)1344 742579
Medical Information e-mail
[email protected]